Effective April 13, 2021, Medicare covers the 3C Patch for the treatment ofchronic non-healing diabetic wounds for 20 weeks.
A large (n=269), multicenter, randomized controlled trial was designed withinput from CMS and approved under the CMS CED program. The study was published in the Lancet Diabetes & Endocrinology, 2018, and served as the basis for the CMS National Coverage Determination. The evidence shows that 3C Patch “is associated with significant enhancement of healing of hard-to-heal foot ulcers in people with diabetes”.
The International Working Group of the Diabetic Foot recommends the use of 3C Patch - an autologous combined leukocyte, platelet and fibrin patch as an adjunctive treatment in diabetic foot ulcers that are difficult to heal.
3C Patch is the first product of its kind utilizing the patient’s own blood, without adding any reagents or additives, to produce a three-layer patch containing leukocyte cells, platelets, and fibrin. 3C Patch is clinically proven to significantly increase the chances of healing chronic diabetic wounds.
POS 11 (office),
19 (outpatient hospital – off campus),
22 (outpatient hospital – on campus),
49 (independent clinic).